Slide 1: 2024 Year End Report
Sustainable healthcare for a new generation 2024 Year End Report February 28, 2025
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
❖ Notes of appreciation ❖ Status of the race Topics for ❖ What to expect for 2025 (and beyond) today ❖ Financial update ❖ Respond to your questions
Slide 4: Key messages for today
Key messages for today Global rapid AST race is on with commercial activity ramping up 1 and first commercial ’next generation’ rapid AST placements Q-linea is the track leader in placed instruments, clinical 2 patients served and clinical evidence delivered 3 2024 demonstrated growth platform is bu
Slide 5: THANK YOU! Some words of appreciation
THANK YOU! | Some words of appreciation for the ones who make it happen • Research and Early Access partners : Italy, Belgium, UK, France, US and beyond Our Lab Partners • Early adopters : first clinical / commercial commitments, customers running commercial evaluations (customers) • Lab & Clinical
Slide 6: ASTar: Revolutionizing AST
ASTar: Revolutionizing AST ~6 ~2 1st Hours Minutes Fully-automated, turn-around time Hands-on time random access platform ➢ Save lives ➢ Simple interface ➢ Comprehensive menu ➢ Save money ➢ Load-and-Go ➢ High reproducibility ➢ Reduces clinical effort ➢ Minimal training need ➢ High throughput with 12
Slide 7: The race is on! Results showing from first laps
The race is on! | Results showing from first laps ❖ Full start in spring 2024 : four FDA clearances ❖ Engineered for results : it is a technical field ❖ Q-linea is track leader : evaluations, win-rate, commercial placements ❖ Outcomes visibility : in-clinic results are the true ‘lap time’
Slide 8: The 'track': Driving shift of patient tests to new standard of care
The ’track’ | Driving shift of patient tests from current to new ’standard of care’ Informational Current Standard-of-Care Emerging Gold Standard Future potential technologies value (rapid AST) ❖ Blood stream infections (~6m) Clinically- ❖ Critical infections : spinal, urgent tests kidney, respirato
Slide 9: Pacing: Fast-evolving commercial pipeline
Pacing | Fast-evolving commercial pipeline 12 – 18 months is ‘normal’ timeframe for end-to-end engagement-to-install process 4 – 6 mths 3 – 6 mths 2 – 6 mths 1– 3 mths INITIAL CUSTOMER CUSTOMER DEMO PURCHASE PROCESS INSTALL & GO LIVE ENGAGEMENT & EVALUATION & NEGOTIATION • Lab planning & preparation
Slide 10: Outlook: Our ambition for the year ahead
Outlook | Our ambition for the year ahead Commercial Progress Clinical Progress Financial Progress ❖ Increasing pace of contracted units ❖ Mounting clinical evidence ❖ Funding 2024 ≤ Q1 ≤ Q2 ≤ Q3 … o LIFETIMES study LPI (last o Rights issue complete (Jan) ❖ First multi-site contract signed (Q1) pati
Slide 11: Financial highlights: Fourth quarter and FY 2024
Financial highlights | Fourth quarter and FY 2024 REVENUES Net sales SEK 0.2 million for the quarter, contracts signed, primarily in Italy with reagent rental model (no capital sale of ASTar in Q4) 2024 FY income amounts to SEK 5.8 million (6.6) OPEX Good control, in line with cost saving program se
Slide 12: OPEX development 2024
OPEX development | 2024 ❖ Reduction in monthly group expenses between H1 and H2 2024 of more than SEK 5 million or SEK 60 million on Personnel expenses + Other external costs an annual basis 25 000 ❖ Cost program implemented during Q2 delivered approx. 20 000 SEK 4 million per month in savings (appr
Slide 13: Funding: Rights issue, directed issue, warrants
Funding | Rights issue, directed issue, warrants ❖ Successful rights issue (and directed issue) - Increase in equity: SEK 205 million (*) - Increase in liquitity: SEK 93 million (*) ❖ No of shares will increase from 117 million to 4.448 billion when completed ❖ Issue using Warrants: max. 2.165 billi
Slide 14: Consolidated statement of financial position
Consolidated statement of financial position | End of fourth quarter ❖ Cash and cash equivalents amounted to SEK 25.7 million (81.9) • SEK 21 million in new loan from main owner Nexttobe received in fourth quarter • Total loans amounted to SEK 99.5 million at end of year; SEK 59 million paid as of F
Slide 15: Future financing
Future financing ❖ Secured financing: Cash at hand 31 of December 2024: SEK 25.7 million Net proceeds from rights issue and directed issue (*): SEK 93.3 million Total financing available: SEK 119 million ❖ Additional financing required for “Going Concern”: SEK 80 million ❖ Additional sources of fina
Slide 16: Thank you! Questions?
Thank Questions? you!